Search for: "BRISTOL-MYERS SQUIBB COMPANY" Results 61 - 80 of 351
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Apr 2019, 9:59 pm by Patent Docs
Increases were notanle for Bristol Myers-Squibb and Takeda, while Sanofi and Gilead showed reduced sales. [read post]
8 Mar 2016, 8:01 am by Dr. Shezad Malik
Nicholas Meyer recently filed against Bristol-Myers Squibb and Otsuka Pharmaceutical Co. in the U.S. [read post]
20 Dec 2014, 10:53 am by Tom Lamb
That is, Bristol-Myers Squibb and Pfizer do not state in these advertisements that there is no FDA-approved antidote for Eliquis as regards its blood-thinner effect at this time. [read post]
10 Mar 2018, 9:12 pm by Patent Docs
Eldora Ellison of Sterne Kessler Goldstein & Fox, PLLC will moderate a panel consisting of Brian Walsh of Bristol-Myers Squibb Company, Andrew Trask of Google LLC, and Jonathan Strang of Latham & Watkins LLP. [read post]
14 Jun 2013, 9:22 pm by Patent Docs
Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff; and Paul Golian, Assistant General Counsel at Bristol-Myers Squibb Company will consider such questions as: • How many and which existing gene patents will be challenged in post-grant proceedings at the USPTO? [read post]
27 Jun 2017, 8:00 am by The Editors
On June 19, 2017, the Supreme Court reinforced its narrow application of specific jurisdiction in mass tort proceedings in an 8-1 decision in Bristol-Myers Squibb Company v. [read post]
5 Aug 2013, 9:59 pm by Patent Docs
The UK High Court recently gave its judgment in the case of Merck, Sharp & Dohme Corp. and Bristol-Myers Squibb Pharmaceuticals Ltd (collectively referred to in the judgement as BMS) v Teva Pharma B.V. and Teva UK Ltd (Teva) (decision). [read post]
9 Jun 2018, 8:58 pm by Patent Docs
Paul Golian of Bristol-Myers Squibb Company, Ali Salimi of the U.S. [read post]
27 Jun 2017, 8:00 am by The Editors
On June 19, 2017, the Supreme Court reinforced its narrow application of specific jurisdiction in mass tort proceedings in an 8-1 decision in Bristol-Myers Squibb Company v. [read post]
30 Mar 2019, 8:49 pm by Patent Docs
Neal Dahiya of Bristol-Myers Squibb Company; Michael Flibbert of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; Michael Rosato of Wilson Sonsini Goodrich & Rosati will also address strategies for obtaining, and opposing, appellate standing. [read post]
1 May 2014, 1:29 am by Ben Vernia
The government had investigated and settled other allegations, but the settlement specifically reserved the relator’s right to pursue certain off-label promotion and kickback charges against Bristol-Myers Squibb for three drugs. [read post]
6 Jun 2016, 1:54 pm by Jeffrey A. Newman
 for example Merck & Co’s drug Keytruda and Bristol Myers Squibb’s Opdivo are being tried together but each drug costs more than $12,500 per month for a total of  $25,000 or $300,000 per year. [read post]
30 Nov 2010, 12:30 pm
In this case, Jeffery Bethune, a former pharmaceutical representative filed a lawsuit against the Bristol-Myers Squibb Company alleging that the company illegally denied him overtime pay for hours he worked over forty. [read post]
16 Dec 2008, 5:16 am
Sanofi-Synthelabo, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively, Sanofi) brought suit under 35 U.S.C. [read post]
12 Feb 2018, 12:05 pm by Tom Lamb
Continuing, this Kombiglyze / Onglyza MDL Transfer Order sets forth the JPML's take on that contention by AstraZeneca, Bristol-Myers Squibb, and McKesson: Defendants concede that most cases involve allegations of heart failure, which is squarely in line with the results of the SAVOR study and the subsequent label change for Onglyza and Kombiglyze XR in April 2016. [read post]